CN1325489C - 取代的烷基氨基哒嗪酮衍生物、其制备方法和含有这种衍生物的药用组合物 - Google Patents

取代的烷基氨基哒嗪酮衍生物、其制备方法和含有这种衍生物的药用组合物 Download PDF

Info

Publication number
CN1325489C
CN1325489C CNB028204425A CN02820442A CN1325489C CN 1325489 C CN1325489 C CN 1325489C CN B028204425 A CNB028204425 A CN B028204425A CN 02820442 A CN02820442 A CN 02820442A CN 1325489 C CN1325489 C CN 1325489C
Authority
CN
China
Prior art keywords
general formula
pyridazin
english
group
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028204425A
Other languages
English (en)
Chinese (zh)
Other versions
CN1571783A (zh
Inventor
J·巴克齐
G·斯米格
P·科特纳吉
G·勒维
I·加斯利
B·马东尼马克
E·施密特
A·埃杰德
H·科姆派尼
C·勒维莱奇
A·米克洛什内科瓦奇
G·桑纳斯
J·韦尔曼
L·G·哈辛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Gyógyszergyár Zrt
Original Assignee
Egis Gyógyszergyár Zrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyógyszergyár Zrt filed Critical Egis Gyógyszergyár Zrt
Publication of CN1571783A publication Critical patent/CN1571783A/zh
Application granted granted Critical
Publication of CN1325489C publication Critical patent/CN1325489C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB028204425A 2001-09-27 2002-09-26 取代的烷基氨基哒嗪酮衍生物、其制备方法和含有这种衍生物的药用组合物 Expired - Fee Related CN1325489C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0103912A HU227237B1 (en) 2001-09-27 2001-09-27 Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
HUP0103912 2001-09-27

Publications (2)

Publication Number Publication Date
CN1571783A CN1571783A (zh) 2005-01-26
CN1325489C true CN1325489C (zh) 2007-07-11

Family

ID=89979721

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB028204425A Expired - Fee Related CN1325489C (zh) 2001-09-27 2002-09-26 取代的烷基氨基哒嗪酮衍生物、其制备方法和含有这种衍生物的药用组合物
CNB028189752A Expired - Fee Related CN100368404C (zh) 2001-09-27 2002-09-26 取代的烷基氨基哒嗪酮衍生物、其制备方法和含有这种衍生物的药用组合物
CN200710104934XA Expired - Fee Related CN101099740B (zh) 2001-09-27 2002-09-26 取代的烷基氨基哒嗪酮衍生物、其制备方法和含有这种衍生物的药用组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNB028189752A Expired - Fee Related CN100368404C (zh) 2001-09-27 2002-09-26 取代的烷基氨基哒嗪酮衍生物、其制备方法和含有这种衍生物的药用组合物
CN200710104934XA Expired - Fee Related CN101099740B (zh) 2001-09-27 2002-09-26 取代的烷基氨基哒嗪酮衍生物、其制备方法和含有这种衍生物的药用组合物

Country Status (25)

Country Link
US (2) US20050043314A1 (enExample)
EP (2) EP1430034B1 (enExample)
JP (2) JP4472337B2 (enExample)
KR (2) KR100911069B1 (enExample)
CN (3) CN1325489C (enExample)
AT (2) ATE288910T1 (enExample)
AU (2) AU2002330656B9 (enExample)
BR (2) BR0212932A (enExample)
CA (2) CA2461467A1 (enExample)
CZ (2) CZ2004528A3 (enExample)
DE (2) DE60202969T2 (enExample)
DK (2) DK1430034T3 (enExample)
EA (2) EA006942B1 (enExample)
ES (2) ES2237696T3 (enExample)
HU (1) HU227237B1 (enExample)
MA (2) MA27137A1 (enExample)
MX (2) MXPA04002836A (enExample)
NO (2) NO326370B1 (enExample)
NZ (2) NZ532104A (enExample)
PL (2) PL369256A1 (enExample)
PT (2) PT1430047E (enExample)
SI (2) SI1430034T1 (enExample)
SK (2) SK1892004A3 (enExample)
WO (2) WO2003027078A1 (enExample)
ZA (2) ZA200402545B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
HU227592B1 (en) * 2002-11-13 2011-09-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Use of substituted alkyl-piridazinone derivatives for the treatment of memory decline and learning malfunctions
JP5147866B2 (ja) * 2007-03-15 2013-02-20 メルク・シャープ・アンド・ドーム・コーポレーション グルカン合成酵素阻害剤として有用であるピリダジノン誘導体
BR112020022006A2 (pt) * 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
CN109053693B (zh) 2018-09-20 2021-02-05 顺毅股份有限公司 哒嗪胺类化合物的制备及其应用
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
TWI902715B (zh) 2019-10-30 2025-11-01 美商律幫治療股份有限公司 作為ｐａｒｐ７抑制劑的嗒酮
WO2022188889A1 (zh) * 2021-03-12 2022-09-15 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
CN115490671B (zh) * 2022-10-21 2024-05-14 水木未来(北京)科技有限公司 Parp7抑制剂及其制备方法
CN118388414A (zh) * 2023-01-17 2024-07-26 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931176A (en) * 1970-11-12 1976-01-06 Sandoz Inc. Hydroxyalkyl substituted-4,5-dihydropyridazin(2H)-3-ones
CN1043129A (zh) * 1988-12-06 1990-06-20 Cl.药物股份公司 新的哌嗪基烷基-3(2h)-哒嗪酮，其制备方法及其作为降血压剂的应用
PL285656A1 (en) * 1990-06-15 1991-12-16 Akad Medyczna Method of obtaining novel 2-aminoalkyl derivatives of 5-aminomethylene-6-/p-chlorophenyl/-4,5-dihydro-2h-pyridazin-3-one
CN1088578A (zh) * 1991-12-20 1994-06-29 埃吉斯药物工厂 3(2h)-哒嗪酮衍生物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU209388B (en) * 1990-12-27 1994-05-30 Richter Gedeon Vegyeszet Process for producing new 3/2h/-pyridazinones and pharmaceutical compositions comprising same
HU224067B1 (hu) 1995-05-29 2005-05-30 Gyógyszerkutató Intézet Kft. 3(2H)-Piridazinon-származékok és e vegyületeket tartalmazó gyógyszerkészítmények
JP2004500314A (ja) 1998-06-05 2004-01-08 エギシュ　ヂョヂセルヂャール　エルテー ３（２ｈ）−ピリダジノン−４−置換アミノ−５−クロロ−誘導体の製法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931176A (en) * 1970-11-12 1976-01-06 Sandoz Inc. Hydroxyalkyl substituted-4,5-dihydropyridazin(2H)-3-ones
CN1043129A (zh) * 1988-12-06 1990-06-20 Cl.药物股份公司 新的哌嗪基烷基-3(2h)-哒嗪酮，其制备方法及其作为降血压剂的应用
PL285656A1 (en) * 1990-06-15 1991-12-16 Akad Medyczna Method of obtaining novel 2-aminoalkyl derivatives of 5-aminomethylene-6-/p-chlorophenyl/-4,5-dihydro-2h-pyridazin-3-one
CN1088578A (zh) * 1991-12-20 1994-06-29 埃吉斯药物工厂 3(2h)-哒嗪酮衍生物及其制备方法

Also Published As

Publication number Publication date
HU0103912D0 (en) 2001-12-28
JP2005508914A (ja) 2005-04-07
HU227237B1 (en) 2010-12-28
AU2002330656A2 (en) 2003-04-07
AU2002330656B2 (en) 2009-04-09
HK1069817A1 (en) 2005-06-03
PT1430034E (pt) 2005-06-30
BR0212839A (pt) 2004-10-13
KR100890667B1 (ko) 2009-03-26
NO20041704L (no) 2004-04-26
JP2005503437A (ja) 2005-02-03
AU2002328166A2 (en) 2003-04-07
CN1558904A (zh) 2004-12-29
ZA200402544B (en) 2005-04-26
SK1902004A3 (en) 2004-10-05
EP1430047A1 (en) 2004-06-23
NZ532104A (en) 2005-10-28
EP1430034A1 (en) 2004-06-23
ZA200402545B (en) 2005-04-26
CA2461510C (en) 2009-07-07
ATE288899T1 (de) 2005-02-15
CN101099740A (zh) 2008-01-09
EP1430047B1 (en) 2005-02-09
MA27068A1 (fr) 2004-12-20
US20040242873A1 (en) 2004-12-02
WO2003027097A1 (en) 2003-04-03
SK1892004A3 (en) 2004-10-05
CA2461467A1 (en) 2003-04-03
SI1430034T1 (en) 2005-08-31
ATE288910T1 (de) 2005-02-15
DE60202969T2 (de) 2006-01-19
NZ532103A (en) 2005-08-26
WO2003027078A1 (en) 2003-04-03
SI1430047T1 (en) 2005-08-31
CZ2004528A3 (cs) 2004-08-18
ES2237690T3 (es) 2005-08-01
HK1115728A1 (en) 2008-12-05
PL369107A1 (en) 2005-04-18
ES2237696T3 (es) 2005-08-01
BR0212932A (pt) 2004-10-13
EA200400469A1 (ru) 2004-08-26
NO326370B1 (no) 2008-11-17
JP4472337B2 (ja) 2010-06-02
US20050043314A1 (en) 2005-02-24
CN1571783A (zh) 2005-01-26
DK1430034T3 (da) 2005-05-30
DE60202970D1 (de) 2005-03-17
HUP0103912A3 (en) 2004-03-01
DE60202969D1 (de) 2005-03-17
KR100911069B1 (ko) 2009-08-06
NO20041551L (no) 2004-06-10
CN100368404C (zh) 2008-02-13
KR20040039446A (ko) 2004-05-10
US6930110B2 (en) 2005-08-16
HK1069816A1 (en) 2005-06-03
CZ2004532A3 (cs) 2004-08-18
CA2461510A1 (en) 2003-04-03
NO325080B1 (no) 2008-01-28
AU2002328166B2 (en) 2008-04-17
MA27137A1 (fr) 2005-01-03
MXPA04002836A (es) 2004-07-05
PL369256A1 (en) 2005-04-18
DE60202970T2 (de) 2006-02-16
EA200400470A1 (ru) 2004-08-26
EA006392B1 (ru) 2005-12-29
MXPA04002838A (es) 2004-07-05
HUP0103912A2 (hu) 2003-07-28
EP1430034B1 (en) 2005-02-09
PT1430047E (pt) 2005-06-30
KR20040039445A (ko) 2004-05-10
DK1430047T3 (da) 2005-06-06
CN101099740B (zh) 2010-09-08
EA006942B1 (ru) 2006-06-30
AU2002330656B9 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
JP4472337B2 (ja) アルキルアミノピリダジノン誘導体、この調製方法、およびこれを含む医薬組成物
AU2002328166A1 (en) Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
JP2005508914A5 (enExample)
AU2002330656A1 (en) Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
HK1069817B (en) Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
HK1069816B (en) Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
HU227294B1 (en) Substituted alkylpyridazone derivatives, process for their preparation and pharmaceutical compositions containing them
MXPA05005137A (es) Alquil-piridazinonas sustituidas para el tratamiento de trastornos de la memoria y del aprendizaje.
HK1115728B (en) Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070711

Termination date: 20110926